Agilent Q3 Revenues Rise 22 Percent as Mass Spec Performs 'Exceptionally Well' | GenomeWeb

Agilent President and CEO William Sullivan said this week that the company’s mass spec business "continues to perform exceptionally well" and contributed to a 22 percent increase in total third-quarter revenue and a 21 percent jump in revenue for the company's Life Sciences business.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.